IMARC Group, a leading market research company, has recently releases report titled “Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global hemoglobinopathies market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Hemoglobinopathies
Hemoglobinopathies refer to a group of genetic disorders characterized by abnormalities in the structure or production of hemoglobin, the protein required for transporting oxygen in red blood cells (RBCs). They are caused by genetic mutations and can be categorized into various types, including sickle cell disease and thalassemia. They are characterized by various symptoms, including a shortage of healthy RBCs, pale skin, yellowing of the skin and eyes, and enlargement of the spleen. They are treated by blood transfusions, bone marrow transplants, and folic acid supplementation. They can also be cured by hydroxyurea, which increases the production of fetal hemoglobin and pain medications for pain.
How Big Is the Hemoglobinopathies Market?
The global hemoglobinopathies market size reached US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.3 Billion by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032.
Request Sample Copy of This Report: https://www.imarcgroup.com/hemoglobinopathies-market/requestsample
What are the growth prospects and trends in the hemoglobinopathies industry?
At present, increasing advancements in genetic research and diagnostics for identifying and characterizing various hemoglobinopathies represent one of the crucial factors impelling the growth of the market.
Besides this, the rising focus on early detection and intervention, ultimately improving patient outcomes, is propelling the growth of the market. In addition, the growing gene therapy and gene modifying systems, such as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, are positively influencing the market.
Apart from this, increasing investments in the development and commercialization of hemoglobinopathy treatments by the governing agencies of various countries and pharmaceutical companies are supporting the growth of the market.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Type:
- Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
- Others
Breakup by Treatment:
- Blood Transfusion
- Stem-cell Transplantation
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
Breakup by Test Type:
- Red Blood Cell (RBC) Count
- Genetic Testing
- High Performance Liquid Chromatography (HPLC)
- Hemoglobin Isoelectric Focusing (Hb IEF)
- Hemoglobin Electrophoresis (Hb ELP)
- Hemoglobin Solubility Test
Breakup by End User:
- Hospitals and Clinics
- Diagnostics Laboratories
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Bio-Rad Laboratories Inc.
- bluebird bio Inc.
- Bristol-Myers Squibb Company
- Danaher Corporation
- Emmaus Life Sciences Inc.
- Gamida-Cell Ltd.
- Global Blood Therapeutics Inc.
- Novartis AG
- PerkinElmer Inc.
- Pfizer Inc.
- Prolong Pharmaceuticals LLC
- Sangamo Therapeutics Inc.
- Sysmex Corporation
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163